EWJ vs XBI
iShares MSCI Japan ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.49% for EWJ.
- • EWJ pays a higher dividend yield (3.83%).
Side-by-side metrics
| Metric | EWJ | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.49% | 0.35% |
Dividend yield Trailing 12-month yield. | 3.83% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $23.40B | $10.92B |
YTD return | 13.91% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.86 | 1.01 |
P/E ratio | 14.99 | — |
Last price | $92.01 | $156.41 |
Inception | — | — |
Issuer | iShares | State Street |
EWJ top holdings
| 8306.T | Mitsubishi UFJ Financial Group Inc | 4.52% |
| 7203.T | Toyota Motor Corp | 3.58% |
| 6857.T | Advantest Corp | 3.14% |
| 6098.T | Recruit Holdings Co Ltd | 3.13% |
| 8316.T | Sumitomo Mitsui Financial Group Inc | 2.89% |
| 6758.T | Sony Group Corp | 2.83% |
| 6501.T | Hitachi Ltd | 2.77% |
| 8035.T | Tokyo Electron Ltd | 2.60% |
| 8411.T | Mizuho Financial Group Inc | 2.21% |
| 9984.T | SoftBank Group Corp | 2.04% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About EWJ
EWJ (iShares MSCI Japan ETF) is Japanese large- and mid-cap equities. Managed by iShares, the fund carries $23.4B in assets under management, an expense ratio of 0.49%, a dividend yield of 3.83%. Its largest holding is Mitsubishi UFJ Financial Group Inc (8306.T), which represents 4.5% of the portfolio. Real Estate is the fund's largest sector exposure at 1.9%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.